evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system.

To investigate the therapeutic potential of mebendazole (MBZ)-loaded nanostructured lipid carriers (NLCs). NLC-MBZ was prepared and characterized to evaluate the and anticancer effects and the inhibitory effect on RanGTP and its potential as an antimetastatic treatment . NLC-MBZ exhibited a size and charge of 155 ± 20 nm and -27 ± 0.5 mV, respectively, with 90.7% encapsulation. Free MBZ and NLC-MBZ had a 50% inhibitory concentration of 610 and 305 nM, respectively, against MDA-MB-231 cell lines. NLC-MBZ decreased tumor size, suppressed tumor lung metastases, and lowered the expression of , ,  and  while boosting the proteins. NLC-MBZ displayed antiangiogenic potential and resulted in a reduced rate of lung metastasis .